{
    "id": "0308",
    "question": "A 50-year-old man with congestive heart failure (CHF) was started on an experimental analog of atrial natriuretic peptide. Which of the following would he expect to experience?",
    "options": {
        "A": "Increased water reabsorption by the renal collecting ducts",
        "B": "Vasoconstriction, increased blood pressure, aldosterone release",
        "C": "Increased glomerular filtration rate, restricted aldosterone release, vascular smooth muscle dilation",
        "D": "Increased plasma calcium and decreased renal reabsorption of phosphate"
    },
    "answer": "C",
    "predict": "{\"step_by_step_thinking\": \"To answer this question, we need to understand the effects of atrial natriuretic peptide (ANP) on the body. ANP is a hormone released by the atria of the heart in response to increased stretch and pressure. It has several effects on the body, including vasodilation, natriuresis, and diuresis. Given the options provided, we can analyze each choice as follows:\\n\\nA. Increased water reabsorption by the renal collecting ducts - This is the opposite of what ANP would cause. ANP promotes diuresis, not water reabsorption.\\n\\nB. Vasoconstriction, increased blood pressure, aldosterone release - This is also the opposite of what ANP would cause. ANP promotes vasodilation and natriuresis, which would decrease blood pressure, not increase it, and would inhibit aldosterone release.\\n\\nC. Increased glomerular filtration rate, restricted aldosterone release, vascular smooth muscle dilation - This option matches the effects of ANP. ANP increases glomerular filtration rate, promotes natriuresis (which would reduce aldosterone release), and causes vasodilation.\\n\\nD. Increased plasma calcium and decreased renal reabsorption of phosphate - ANP does not have a direct effect on plasma calcium levels or renal phosphate reabsorption. Its main effects are on vasodilation, natriuresis, and diuresis.\\n\\nBased on the effects of ANP, the correct answer is C.\", \"answer_choice\": \"C\"}}",
    "snippets": [
        {
            "id": "InternalMed_Harrison_18240",
            "title": "InternalMed_Harrison",
            "content": "on HF hospitalizations, counterbalanced, however, by an increase in adverse effects, particularly hyperkalemia. However, pessimism has been generated by the negative outcome of the Aldosterone Receptor Blockade in Diastolic Heart Failure (ALDO-DHF) study wherein spironolactone improved echocardiographic indices of diastolic dysfunction but failed to improve exercise capacity, symptoms, or quality-of-life measures. A unique molecule that hybridizes an ARB with an endopeptidase inhibitor, LCZ696, increases the generation of myocardial cyclic guanosine 3\u2032,5\u2032-monophosphate, enhances myocardial relaxation, and reduces ventricular hypertrophy. This dual blocker has been shown to reduce circulating natriuretic peptides and reduce left atrial size to a significantly greater extent than valsartan alone in patients with HFpEF."
        },
        {
            "id": "Pharmacology_Katzung_1297",
            "title": "Pharmacology_Katzung",
            "content": "A synthetic form of the endogenous peptide brain natriuretic peptide (BNP) is approved for use in acute (not chronic) cardiac failure as nesiritide. This recombinant product increases cGMP in smooth muscle cells and reduces venous and arteriolar tone in experimental preparations. It also causes diuresis. However, large trials with this drug have failed to show an improvement in mortality or rehospitalizations. The peptide has a short half-life of about 18 minutes and is administered as a bolus intravenous dose followed by continuous infusion. Excessive hypotension is the most common adverse effect. Reports of significant renal damage and deaths have resulted in extra warnings regarding this agent, and it should be used with great caution. A newer approach to modulation of the natriuretic peptide system is inhibition of the neutral endopeptidase enzyme, neprilysin, which is responsible for the degradation of BNP and atrial natriuretic peptide (ANP), as well as angiotensin II,"
        },
        {
            "id": "Pharmacology_Katzung_1832",
            "title": "Pharmacology_Katzung",
            "content": "The serum concentration of endogenous BNP rises in heart failure, and monitoring this peptide has been shown to have prognostic value. Natriuretic peptides may be administered as recombinant ANP (carperitide), recombinant BNP (nesiritide), or ularitide, the synthetic form of urodilatin (see above). These peptides produce vasodilation and natriuresis and have been investigated for the treatment of congestive heart failure. Nesiritide is approved for the treatment of decompensated acute heart failure (see Chapter 13). Ularitide has demonstrated beneficial effects in animal models of heart failure and in phase 1 and 2 studies in heart failure patients (Figure 17\u20136). It is in phase 3 development as an infusion treatment for acute decompensated heart failure. The circulating levels of natriuretic peptides can also be increased by drugs that inhibit their breakdown by neprilysin 7.5 ng/kg/min"
        },
        {
            "id": "InternalMed_Harrison_18245",
            "title": "InternalMed_Harrison",
            "content": "Heart Failure: Management Heart Failure with Preserved Ejection Fraction: Management \u2022 Reduce the congestive state \u2013 Caution to not reduce preload excessively \u2013 Efforts to maintain sinus rhythm in atrial fibrilation may be beneficial \u2013 May mimic HF as an \u201cangina equivalent\u201d \u2013 Common comorbidity causing systemic hypertension, pulmonary hypertension, and right heart dysfunction \u2013 ? Targeted pacing (unproven) FIGURE 280-1 Pathophysiologic correlations, general therapeutic principles, and results of specific \u201cdirected\u201d therapy in heart failure (HF) with preserved ejection fraction. ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker."
        },
        {
            "id": "Pharmacology_Katzung_1830",
            "title": "Pharmacology_Katzung",
            "content": "The natriuretic peptides have a short half-life in the circulation. They are metabolized in the kidneys, liver, and lungs by the neutral endopeptidase NEP 24.11 (neprilysin). Inhibition of this endopeptidase results in increases in circulating levels of the natriuretic peptides, natriuresis, and diuresis. The peptides are also removed from the circulation by binding to ANP-C receptors in the vascular endothelium. This receptor binds the natriuretic peptides with equal affinity. The receptor and bound peptide are internalized, the peptide is degraded enzymatically, and the receptor is returned to the cell surface. Patients with heart failure have high plasma levels of ANP and BNP; the latter has emerged as a diagnostic and prognostic marker in this condition. Signaling? Peptide degradation EndocytosisReceptor IDE recycling NEPNPR-A GC-ANPR-A GC-ANPR-B GC-BNPR-B GC-B ANP=CNP>BNP Ring cleavage Tail cleavage GTP cGMP GTP cGMP cGMP GTP IntracellularNPR-CNPR-C"
        },
        {
            "id": "InternalMed_Harrison_20550",
            "title": "InternalMed_Harrison",
            "content": "CHF, congestive heart failure; CT, computed tomography; LDH, lactate dehydrogenase; PE, pulmonary embolism; PF, pleural fluid; TB, tuberculosis. a diagnostic thoracentesis should be performed if the effusions are not bilateral and comparable in size, if the patient is febrile, or if the patient has pleuritic chest pain to verify that the patient has a transudative effusion. Otherwise the patient\u2019s heart failure is treated. If the effusion persists despite therapy, a diagnostic thoracentesis should be performed. A pleural fluid N-terminal pro-brain natriuretic peptide (NT-proBNP) >1500 pg/mL is virtually diagnostic that the effusion is secondary to congestive heart failure."
        },
        {
            "id": "Pharmacology_Katzung_1825",
            "title": "Pharmacology_Katzung",
            "content": "The atria and other tissues of mammals contain a family of peptides with natriuretic, diuretic, vasorelaxant, and other properties. The family includes atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP), and C-type natriuretic peptide (CNP). The peptides share a common 17-amino-acid disulfide ring with variable Cand N-terminals. A fourth peptide, urodilatin, has the same structure as ANP with an extension of four amino acids at the N-terminal. The renal effects of these peptides are discussed in Chapter 15. ANP is derived from the carboxyl terminal end of a common precursor termed preproANP. ANP is synthesized primarily in cardiac atrial cells, but it is also synthesized in ventricular myocardium, by neurons in the central and peripheral nervous systems, and in the lungs."
        },
        {
            "id": "InternalMed_Harrison_17298",
            "title": "InternalMed_Harrison",
            "content": "bradykinin, and the natriuretic peptides (atrial natriuretic peptide [ANP], brain natriuretic peptide [BNP], C-type natriuretic peptide [CNP], and dendroaspis natriuretic peptide [DNP]), as discussed above."
        },
        {
            "id": "Biochemistry_Lippincott_1323",
            "title": "Biochemistry_Lippinco",
            "content": "For Questions 27.7 and 27.8, use the following case. A sedentary 50-year-old man weighing 176 lb (80 kg) requests a physical. He denies any health problems. Routine blood analysis is unremarkable except for plasma total cholesterol of 295 mg/dl. (Reference value is <200 mg.) The man refuses drug therapy for his hypercholesterolemia. Analysis of a 1-day dietary recall showed the following: 7.4. Decreasing which one of the following dietary components would have the greatest effect in lowering the patient\u2019s plasma cholesterol? A. Carbohydrates B. Cholesterol C. Fiber D. Monounsaturated fat E. Polyunsaturated fat F. Saturated fat"
        },
        {
            "id": "Pharmacology_Katzung_1335",
            "title": "Pharmacology_Katzung",
            "content": "A 69-year-old retired teacher presents with a 1-month history of palpitations, intermittent shortness of breath, and fatigue. She has a history of hypertension. An electrocardiogram (ECG) shows atrial fibrillation with a ventricular response of 122 beats/min (bpm) and signs of left ventricular hypertrophy. She is anticoagulated with warfarin and started on sustained-release metoprolol, 50 mg/d. After 7 days, her rhythm reverts to normal sinus rhythm spontaneously. However, over the ensuing month, she continues to have intermittent palpita-tions and fatigue. Continuous ECG recording over a 48-hour period documents paroxysms of atrial fibrillation with heart rates of 88\u2013114 bpm. An echocardiogram shows a left ven-tricular ejection fraction of 38% (normal \u2265 60%) with no localized wall motion abnormality. At this stage, would you initiate treatment with an antiarrhythmic drug to maintain normal sinus rhythm, and if so, what drug would you choose?"
        },
        {
            "id": "InternalMed_Harrison_18183",
            "title": "InternalMed_Harrison",
            "content": "FIGURE 279-1 Pathogenesis of heart failure with a depressed ejection fraction. Heart failure begins after an index event produces an initial decline in the heart's pumping capacity. After this initial decline in pumping capacity, a variety of compensatory mechanisms are activated, including the adrenergic nervous system, the reninangiotensin-aldosterone system, and the cytokine system. In the short term, these systems are able to restore cardiovascular function to a normal homeostatic range with the result that the patient remains asymptomatic. However, with time, the sustained activation of these systems can lead to secondary end-organ damage within the ventricle, with worsening left ventricular remodeling and subsequent cardiac decompensation. (From D Mann: Circulation 100:999, 1999.) to sustain and modulate LV function for a period of months to years. The compensatory mechanisms that have been described thus far include (1) activation of the renin-angiotensin-aldosterone (RAA) and"
        },
        {
            "id": "InternalMed_Harrison_2762",
            "title": "InternalMed_Harrison",
            "content": "Laboratory studies should include electrocardiography to seek evidence of ventricular hypertrophy and prior myocardial infarction. Echocardiography is indicated when systolic dysfunction, pulmonary hypertension, or valvular heart disease is suspected. Bronchoprovocation testing is useful in patients with intermittent symptoms suggestive of asthma but normal physical examination and lung function; up to one-third of patients with the clinical diagnosis of asthma do not have reactive airways disease when formally tested. Measurement of brain natriuretic peptide levels in serum is increasingly used to assess for CHF in patients presenting with acute dyspnea but may be elevated in the presence of right ventricular strain as well."
        },
        {
            "id": "Pharmacology_Katzung_1333",
            "title": "Pharmacology_Katzung",
            "content": "The patient has a low ejection fraction with systolic heart failure, probably secondary to hypertension. His heart fail-ure must be treated first, followed by careful control of the hypertension. He was initially treated with a diuretic (furo-semide, 40 mg twice daily). On this therapy, he was less short of breath on exertion and could also lie flat without dyspnea. An angiotensin-converting enzyme (ACE) inhib-itor was added (enalapril, 20 mg twice daily), and over the next few weeks, he continued to feel better. Because of continued shortness of breath on exercise, digoxin at 0.25 mg/d was added with a further modest improvement in exercise tolerance. The blood pressure stabilized at 150/90 mm Hg, and the patient will be educated regarding the relation between his hypertension and heart failure and the need for better blood pressure control. Cautious addition of a \u03b2 blocker (metoprolol) will be considered. Blood lipids, which are currently in the normal range, will be monitored."
        },
        {
            "id": "InternalMed_Harrison_18235",
            "title": "InternalMed_Harrison",
            "content": "history. In advanced heart failure, a stage of disease typically encountered in HFrEF, the patient remains markedly symptomatic with demonstrated refractoriness or inability to tolerate full-dose neurohormonal antagonism, often requires escalating doses of diuretics, and exhibits persistent hyponatremia and renal insufficiency with frequent episodes of heart failure decompensation requiring recurrent hospitalizations. Such individuals are at the highest risk of sudden or progressive pump failure\u2013related deaths (Chap. 281). In contrast, early-stage asymptomatic left ventricular dysfunction is amenable to preventive care, and its natural history is modifiable by neurohormonal antagonism (not further discussed)."
        },
        {
            "id": "InternalMed_Harrison_19156",
            "title": "InternalMed_Harrison",
            "content": "Angina and Heart Failure Transient left ventricular failure with angina can be controlled by the use of nitrates. For patients with established congestive heart failure, the increased left ventricular wall tension raises myocardial oxygen demand. Treatment of congestive heart failure with an ACE inhibitor, a diuretic, and digoxin (Chap. 279) reduces heart size, wall tension, and myocardial oxygen demand, which helps control angina and ischemia. If the symptoms and signs of heart failure are controlled, an effort should be made to use beta blockers not only for angina but because trials in heart failure have shown significant improvement in survival. A trial of the intravenous ultra-short-acting beta blocker esmolol may be useful to establish the safety of beta blockade in selected patients. Nocturnal angina often can be relieved by the treatment of heart failure."
        },
        {
            "id": "InternalMed_Harrison_2862",
            "title": "InternalMed_Harrison",
            "content": "Atrial distention causes release into the circulation of atrial natriuretic peptide (ANP), a polypeptide; a high-molecular-weight precursor of ANP is stored in secretory granules within atrial myocytes. The closely related brain natriuretic peptide (pre-prohor-251 mone BNP) is stored primarily in ventricular myocytes and is released when ventricular diastolic pressure rises. Released ANP and BNP (which is derived from its precursor) bind to the natriuretic receptor-A, which causes: (1) excretion of sodium and water by augmenting glomerular filtration rate, inhibiting sodium reabsorption in the proximal tubule, and inhibiting release of renin and aldosterone; and (2) dilation of arterioles and venules by antagonizing the vasoconstrictor actions of AII, AVP, and sympathetic stimulation. Thus, elevated levels of natriuretic peptides have the capacity to oppose sodium retention in hypervolemic and edematous states."
        },
        {
            "id": "Pharmacology_Katzung_808",
            "title": "Pharmacology_Katzung",
            "content": "A 68-year-old man presents with a complaint of light-headedness on standing that is worse after meals and in hot environments. Symptoms started about 4 years ago and have slowly progressed to the point that he is disabled. He has fainted several times but always recovers conscious-ness almost as soon as he falls. Review of symptoms reveals slight worsening of constipation, urinary retention out of proportion to prostate size, and decreased sweating. He is otherwise healthy with no history of hypertension, diabetes, or Parkinson\u2019s disease. Because of urinary retention, he was placed on the \u03b11 antagonist tamsulosin, but the fainting spells got worse. Physical examination revealed a blood pres-sure of 167/84 mm Hg supine and 106/55 mm Hg standing. There was an inadequate compensatory increase in heart rate (from 84 to 88 bpm), considering the degree of ortho-static hypotension. Physical examination is otherwise unre-markable with no evidence of peripheral neuropathy or parkinsonian"
        },
        {
            "id": "Obstentrics_Williams_377",
            "title": "Obstentrics_Williams",
            "content": "Large amounts of intramuscular progesterone given during late labor delay this diminishing refractoriness. At least two species of these-atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP)-are secreted by cardiomyocytes in response to chamber-wall stretching. These peptides regulate blood volume by provoking natriuresis, diuresis, and vascular smooth-muscle relaxation. In nonpregnant and pregnant patients, levels of BNP and of amino-terminal pro-brain natriuretic peptide (Nt pro-BNP), as well as newer analytes such as suppressor of tumorigenicity 2 (ST2), may be useful in screening for depressed left ventricular systolic function and determining chronic heart failure prognosis (Ghashghaei, 2016)."
        },
        {
            "id": "InternalMed_Harrison_18217",
            "title": "InternalMed_Harrison",
            "content": "Biomarkers Circulating levels of natriuretic peptides are useful and important adjunctive tools in the diagnosis of patients with HF. Both B-type natriuretic peptide (BNP) and N-terminal pro-BNP (NT-proBNP), which are released from the failing heart, are relatively sensitive markers for the presence of HF with depressed EF; they also are elevated in HF patients with a preserved EF, albeit to a lesser degree. In ambulatory patients with dyspnea, the measurement of BNP or NT-proBNP is useful to support clinical decision making regarding the diagnosis of HF, especially in the setting of clinical uncertainty. Moreover, the measurement of BNP or NT-proBNP is useful for establishing prognosis or disease severity in chronic HF and can be useful to achieve optimal dosing of medical therapy in select clinically euvolemic patients. However, it is important to recognize that natriuretic peptide levels increase with age and renal impairment, are more elevated in women, and can be elevated in"
        },
        {
            "id": "Pharmacology_Katzung_4332",
            "title": "Pharmacology_Katzung",
            "content": "George P. Chrousos, MD A 19-year-old man complains of anorexia, fatigue, dizziness, and weight loss of 8 months\u2019 duration. The examining physician discovers postural hypotension and moderate vitiligo (depigmented areas of skin) and obtains routine blood tests. She finds hyponatremia, hyperkalemia, and acidosis and suspects Addison\u2019s disease. She performs a standard ACTH 1\u201324 stimulation test, which reveals an insufficient plasma cortisol response compatible with primary adrenal insuf-ficiency. The diagnosis of autoimmune Addison\u2019s disease is made, and the patient must start replacement of the hormones he cannot produce himself. How should this patient be treated? What precautions should he take?"
        },
        {
            "id": "InternalMed_Harrison_21445",
            "title": "InternalMed_Harrison",
            "content": "Chronic exposure to aldosterone causes a decrease in urinary Na+ excretion lasting only a few days, after which Na+ excretion returns to previous levels. This phenomenon, called aldosterone escape, is explained by decreased proximal tubular Na+ reabsorption following blood volume expansion. Excess Na+ that is not reabsorbed by the proximal tubule overwhelms the reabsorptive capacity of more distal nephron segments. This escape may be facilitated by atrial natriuretic peptides that lose their effectiveness in the clinical settings of heart failure, nephrotic syndrome, and cirrhosis, leading to severe Na+ retention and volume overload."
        },
        {
            "id": "InternalMed_Harrison_18234",
            "title": "InternalMed_Harrison",
            "content": "Distinctive phenotypes of presentation with diverse management targets exemplify the vast syndrome of heart failure. These range from chronic heart failure with reduced ejection fraction (HFrEF) or heart failure with preserved ejection fraction (HFpEF), acute decompensated heart failure (ADHF), and advanced heart failure. Early management evolved from symptom control to disease-modifying therapy in HFrEF with the advent of renin-angiotensin-aldosterone system (RAAS)\u2013 directed therapy, beta receptor antagonists, mineralocorticoid receptor antagonists, cardiac resynchronization therapy, and implantable cardio-defibrillators. However, similar advances have been elusive in the syndromes of HFpEF and ADHF, which have remained devoid of convincing therapeutic advances to alter their natural history. In advanced heart failure, a stage of disease typically encountered in HFrEF, the patient remains markedly symptomatic with demonstrated refractoriness or inability to tolerate full-dose"
        },
        {
            "id": "Physiology_Levy_3493",
            "title": "Physiology_Levy",
            "content": "by the kidneys. The RAAS is suppressed with ECFV expansion, and renal NaCl excretion is therefore enhanced. The body produces a number of substances that act on the kidneys to increase NaCl excretion (see ). Of these, natriuretic peptides produced by the heart and kidneys are best understood and will be the focus of the following discussion. The heart produces two natriuretic peptides. Atrial myocytes produce and store the peptide hormone ANP, and ventricular myocytes produce and store BNP. Both peptides are secreted when the heart dilates (i.e., during volume expansion, with heart failure), and they relax vascular smooth muscle and promote NaCl and water excretion by the kidneys. The kidneys also produce a related natriuretic peptide termed urodilatin. Its actions are limited to promoting NaCl excretion by the kidneys. In general the actions of these natriuretic peptides as they relate to renal NaCl and water excretion antagonize those of the RAAS. These actions include: 1."
        },
        {
            "id": "Pharmacology_Katzung_1243",
            "title": "Pharmacology_Katzung",
            "content": "Tadalafil Cialis, Adcirca Cilostazol Generic, Pletal Pentoxifylline Generic, Trental Bertram G. Katzung, MD, PhD* A 55-year-old man noticed shortness of breath with exer-tion while on a camping vacation in a national park. He has a 15-year history of poorly controlled hypertension. The shortness of breath was accompanied by onset of swelling of the feet and ankles and increasing fatigue. On physical examination in the clinic, he is found to be mildly short of breath lying down but feels better sitting upright. Pulse is 100 bpm and regular, and blood pressure is 165/100 mm Hg. Crackles are noted at both lung bases, and his jugular venous pressure is elevated. The liver is enlarged, and there is 3+ edema of the ankles and feet. An echocardiogram shows an enlarged, poorly contracting heart with a left ven-tricular ejection fraction of about 30% (normal: 60%). The presumptive diagnosis is stage C, class III heart failure with reduced ejection fraction. What treatment is indicated?"
        },
        {
            "id": "Gynecology_Novak_3737",
            "title": "Gynecology_Novak",
            "content": "Table 22.17 Signs and Symptoms of Congestive Heart Failure 1. Presence of an S3 gallop 2. 3. Lateral shift of the point of maximal impulse 4. 5. 6. 7. Evidence of pulmonary edema or cardiac enlargement on chest radiograph 8. perform usual daily activities without developing CHF are at limited risk of perioperative heart failure. To prevent severe postoperative complications, CHF must be corrected preoperatively."
        },
        {
            "id": "Pharmacology_Katzung_287",
            "title": "Pharmacology_Katzung",
            "content": "Pharmacokinetics & Pharmacodynamics: Rational Dosing & the Time Course of Drug Action Nicholas H. G. Holford, MB, ChB, FRACP is 1 ng/mL. Tablets of digoxin are available that contain 62.5 micrograms (mcg) and 250 mcg. What maintenance dose would you recommend? An 85-year-old, 60-kg woman with a serum creatinine of 1.8 mg/dL has atrial fibrillation. A decision has been made to use digoxin to control the rapid heart rate. The target con-centration of digoxin for the treatment of atrial fibrillation"
        },
        {
            "id": "Obstentrics_Williams_6455",
            "title": "Obstentrics_Williams",
            "content": "In women with an underlying cardiomyopathy, heart failure is commonly precipitated by preeclampsia, hypertension, hemorrhage and anemia, and puerperal sepsis (Cunningham, 1986; Sibai, 1987). In many of these, when echocardiography is done later, systolic function is normal as measured by ejection fraction, but evidence for diastolic dysunction can often be found (Aurigemma, 2004). The use of brain natriuretic peptide (BNP) has not been evaluated extensively in pregnancy (Seror, 2014). his neurohormone is secreted from ventricle myocytes and fibroblasts with distention seen in heart failure. In nonpregnant patients, values < 100 pgl mL have an excellent negative-predictive value, and levels >500 pg/mL have an excellent positivepredictive value. It is problematic that levels frequently are 100 to 500 pg/mL, and thus nondiagnostic (Ware, 2005). Values for N-terminal BNP and atrial natriuretic peptide (ANP) are both elevated with preeclampsia (Szabo, 2014; Tihtonen, 2007). his is"
        },
        {
            "id": "Pharmacology_Katzung_2624",
            "title": "Pharmacology_Katzung",
            "content": "Helge Eilers, MD, & Spencer Yost, MD An elderly man with type 2 diabetes mellitus and ischemic pain in the lower extremity is scheduled for femoral-to-popliteal artery bypass surgery. He has a history of hyper-tension and coronary artery disease with symptoms of stable angina. He can walk only half a block before pain in his legs forces him to stop. He has a 50-pack-year smoking history but stopped 2 years ago. Medications include atenolol, atorvastatin, and hydrochlorothiazide. The nurse in the preoperative holding area obtains the following vital signs: temperature 36.8\u00b0C (98.2\u00b0F), blood pressure 168/100 mm Hg, heart rate 78 bpm, oxygen saturation by pulse oximeter 96% while breathing room air, and pain 5/10 in the right lower leg after walking into the hospital. What anesthetic agents will you choose for his anesthetic plan? Why? Does the choice of anesthetic make a difference?"
        },
        {
            "id": "Pharmacology_Katzung_914",
            "title": "Pharmacology_Katzung",
            "content": "David Robertson, MD, & Italo Biaggioni, MD* A 38-year-old man has been experiencing palpitations and headaches. He enjoyed good health until 1 year ago when spells of rapid heartbeat began. These became more severe and were eventually accompanied by throbbing headaches and drenching sweats. Physical examination revealed a blood pressure of 150/90 mm Hg and heart rate of 88 bpm. During the physical examination, palpation of the abdomen elicited a sudden and typical episode, with a rise in blood pressure to 210/120 mm Hg, heart rate to 122 bpm, profuse sweating, and facial pallor. This was accompanied by severe headache. What is the likely cause of his episodes? What caused the blood pressure and heart rate to rise so high during the examination? What treatments might help this patient?"
        },
        {
            "id": "Pharmacology_Katzung_1265",
            "title": "Pharmacology_Katzung",
            "content": "failure) may mediate negative inotropic effects. Excessive \u03b2 activation can lead to leakage of calcium from the SR via RyR channels and contributes to stiffening of the ventricles and arrhythmias. Reuptake of Ca2+ into the SR by SERCA may also be impaired. Prolonged \u03b2 activation also increases caspases, the enzymes responsible for apoptosis. Increased angiotensin II production leads to increased aldosterone secretion (with sodium and water retention), to increased afterload, and to remodeling of both heart and vessels. Other hormones are released, including natriuretic peptide, endothelin, and vasopressin (see Chapter 17). Of note, natriuretic peptides released from the heart and possibly other tissues include N-terminal pro-brain natriuretic peptide (NT-proBNP), which has come into use as a surrogate marker for the presence and severity of heart failure. Within the heart, failure-induced changes have been documented in calcium handling in the SR by SERCA and phospholamban; in"
        },
        {
            "id": "Surgery_Schwartz_413",
            "title": "Surgery_Schwartz",
            "content": "during short-term fasting with an approximate basal energy expenditure of 1800 kcal. During starvation, muscle proteins and fat stores provide fuel for the host, with the latter being most abundant. RBC = red blood cell; WBC = white blood cell. activation of Phospholipase A2. Antagonists to PAF recep-tors have been experimentally shown to mitigate the effects of ischemia and reperfusion injury. Of note, human sepsis is associated with a reduction in the levels of PAF-acetylhydro-lase, which inactivates PAF by removing an acetyl group. Indeed, PAF-acetylhydrolase administration in patients with severe sepsis has yielded some reduction in multiple organ dysfunction and mortality234; however, larger phase III clinical trials failed to show benefit.Natriuretic PeptidesThe natriuretic peptides, atrial natriuretic factor (ANP) and brain natriuretic peptide (BNP), are a family of peptides that are released primarily by atrial and ventricular tissue respectively, but are also synthesized by"
        },
        {
            "id": "Pharmacology_Katzung_1006",
            "title": "Pharmacology_Katzung",
            "content": "Neal L. Benowitz, MD A 35-year-old man presents with a blood pressure of 150/95 mm Hg. He has been generally healthy, is sedentary, drinks several cocktails per day, and does not smoke cigarettes. He has a family history of hypertension, and his father died of a myocardial infarction at age 55. Physical examination is remarkable only for moderate obesity. Total cholesterol is 220, and high-density lipoprotein (HDL) cholesterol level is 40 mg/dL. Fasting glucose is 105 mg/dL. Chest X-ray is normal. Electrocardiogram shows left ven-tricular enlargement. How would you treat this patient?"
        }
    ],
    "scores": [
        0.027846763836830705,
        0.025752580864598987,
        0.022808088138276818,
        0.021812168274635918,
        0.020203084564938564,
        0.01951637471439452,
        0.019228283502772767,
        0.019129362893025997,
        0.01904761904761905,
        0.018967997123336928,
        0.01896117900790798,
        0.018746211059767728,
        0.017542515703998774,
        0.01720573032048442,
        0.017011197243755383,
        0.01691407365115615,
        0.016530054644808743,
        0.01652780600149021,
        0.016511458952513044,
        0.016488651535380507,
        0.016202498698594484,
        0.016133162612035852,
        0.016078164615670028,
        0.01606580553948975,
        0.016035353535353535,
        0.015335772707705553,
        0.015258417942981703,
        0.015247283211355067,
        0.01493453355155483,
        0.014869281045751633,
        0.014668817421111001,
        0.01422170270796805
    ]
}